Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "Market"

3901 News Found

Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
Biopharma | January 23, 2026

Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery

This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market


EMA hits record high in vet medicine nods for second year running
News | January 23, 2026

EMA hits record high in vet medicine nods for second year running

EMA recommended 30 veterinary medicines for marketing authorisation in 2025


Functional Gut Clinic launches UK’s first boutique GI clinical trials division
Clinical Trials | January 23, 2026

Functional Gut Clinic launches UK’s first boutique GI clinical trials division

Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced


CORONA Remedies secures EAEU-GMP certification
News | January 23, 2026

CORONA Remedies secures EAEU-GMP certification

This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model


Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
News | January 23, 2026

Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator

This marks the second indication for which gumokimab has gained NDA review acceptance


Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries
News | January 21, 2026

Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries

Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally


Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
News | January 21, 2026

Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.